Commentary

Video

Dr Dalia Rotstein Lists Barriers to Equitable MS Research, Care Delivery

Dalia Rotstein, MD, MPH, assistant professor of medicine at the University of Toronto, lists barriers to multiple sclerosis (MS) research and care delivery.

Dalia Rotstein, MD, MPH, assistant professor of medicine at the University of Toronto, lists barriers to multiple sclerosis (MS) research and care delivery.

The topic was discussed on February 29 at the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2024 during the session Rotstein cochaired titled "MS Across Populations and Access to Care."

Transcript

What specific barriers are there to equitable MS research and care delivery?

I think we are facing many barriers today to equitable MS care and also to research. Firstly, I think we have to consider different social determinants of health, and, as highlighted in this session, access to neurologic care is also a key factor.

So, social determinants of health include factors like income, sex, age, race, and ethnicity; also, what the built environment looks like. So, what does the neighborhood that a person lives in look like in terms of access to medical centers, availability of nutritious food, and community support; are they in a situation with social isolation?

All of these factors are very important when we're considering equity goals. I think that, as we saw in recent research that was highlighted by [Marisa McGinley, DO, of Cleveland Clinic], there are many disparities. We observed disparities and access to neurologic care across rural and urban communities in the United States and also across different racial and ethnic communities. The Hispanic and Black communities have lower access to specialized neurologic care, especially MS neurologists.

We need to think about creative solutions for approaching that. I think it's important to engage those different communities and try to find out how we can deliver care in a more accessible manner. Also, there were some novel solutions proposed, such as using telemedicine, for example, to reach people in a more convenient way. I think there are a lot of promising avenues for the future, but there's a lot of work that needs to be done.

Related Videos
Io Hui, PhD, researcher at The University of Edinburgh
Adam Colborn, JD, of AMCP
Corey McEwen, PharmD, MS
Daniel Howell, MBBS
Jonathan Kurman, MD
Tetyana Kendzerska, MD
Krunal Patel, MD
Scott Manaker,MD
Juan Carlos Martinez, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo